Research from Boston
Researchers from Massachusetts General Hospital and the Broad Institute of MIT and Harvard studied RSV viral lineages during the surge of RSV infections in 2022.
They used genome sequencing to sequence 105 samples of patients diagnosed with RSV infection who visited the Massachusetts General Hospital or its outpatient practices. Genome sequencing gives scientists information about the composition of the virus’s genome, leading to the identification of strains or mutations. The authors believed their samples to be representative of the overall United States.
From the 77 usable gene sequences, they detected multiple strains of RSV-A (70 samples) and RSV-B (7 samples). Tracing back the sequences, the most recent common ancestor of the RSV-A strains was estimated to have existed between 2014-2017, and for RSV-B strains it was estimated to have been in 2019. No new virulent strains were identified.
This work shows that while the RSV virus also evolves, it is much slower than the flu virus.
Research from Washington State
In their article published in the CDC’s Emerging Infectious Diseases journal, researchers from the University of Washington and the Fred Hutchinson Cancer Research Center studied the genomes of RSV virus strains in King County, Washington for two seasons- 2021-2022, and 2022-2023.
Dr. Stephanie Goya and colleagues extracted RNA from excess samples obtained from individuals who sought care at the University of Washington during these seasons, and whose samples were checked positive for RSV by PCR. A majority of these patients were outpatients.
Among 54 samples, they found 31 samples to have the RSV-A subtype (1 from 2021-22, and 30 from 2022-23) and 23 samples to have the RSV-B subtype (13 from 2021-22, and 10 from 2022-23). In these subtypes, the researchers identified strains that have been circulating in the U.S. over the last 10 years, suggesting that the virus does not mutate often.
In their article, the researchers say, “Detected RSV strains have been spreading for >10 years, suggesting a role for diminished population immunity from low RSV exposure during the COVID-19 pandemic”.
They also caution that continued efforts to sequence RSV strains are necessary to keep track of possible future mutations, saying, “With likely future widespread availability of RSV vaccines, continued real-time RSV genomic surveillance will be required to monitor the evolution and emergence of new viral strains”.